Stoke Therapeutics (STOK) Competitors $28.87 -1.03 (-3.44%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STOK vs. MRUS, KRYS, PTCT, MENS, ARWR, ACLX, PCVX, CRNX, PTGX, and KYMRShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Merus (MRUS), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Vaxcyte (PCVX), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Its Competitors Merus Krystal Biotech PTC Therapeutics Jyong Biotech Arrowhead Pharmaceuticals Arcellx Vaxcyte Crinetics Pharmaceuticals Protagonist Therapeutics Kymera Therapeutics Stoke Therapeutics (NASDAQ:STOK) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Which has stronger valuation & earnings, STOK or MRUS? Stoke Therapeutics has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$199.89M7.91-$88.98M$0.8533.96Merus$56.23M127.11-$215.33M-$5.50-17.18 Which has more risk and volatility, STOK or MRUS? Stoke Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Merus has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Does the media prefer STOK or MRUS? In the previous week, Stoke Therapeutics had 17 more articles in the media than Merus. MarketBeat recorded 25 mentions for Stoke Therapeutics and 8 mentions for Merus. Stoke Therapeutics' average media sentiment score of 0.42 beat Merus' score of 0.39 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 5 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merus 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer STOK or MRUS? Stoke Therapeutics presently has a consensus target price of $27.43, suggesting a potential downside of 4.99%. Merus has a consensus target price of $93.12, suggesting a potential downside of 1.46%. Given Merus' higher possible upside, analysts plainly believe Merus is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00Merus 1 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.16 Do insiders & institutionals hold more shares of STOK or MRUS? 96.1% of Merus shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 3.7% of Merus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is STOK or MRUS more profitable? Stoke Therapeutics has a net margin of 26.25% compared to Merus' net margin of -685.64%. Stoke Therapeutics' return on equity of 18.32% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.25% 18.32% 15.48% Merus -685.64%-50.28%-42.00% SummaryStoke Therapeutics beats Merus on 13 of the 17 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.58B$3.36B$6.12B$10.64BDividend YieldN/A2.29%5.66%4.69%P/E Ratio33.9222.1586.1127.75Price / Sales7.91419.64588.17183.92Price / CashN/A47.1938.3262.20Price / Book6.6810.3912.976.80Net Income-$88.98M-$52.40M$3.30B$275.97M7 Day Performance12.95%4.11%3.27%2.08%1 Month Performance27.41%15.96%10.12%9.09%1 Year Performance153.25%33.37%83.41%36.72% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics3.0773 of 5 stars$28.87-3.4%$27.43-5.0%+150.2%$1.58B$199.89M33.92100Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionMRUSMerus0.9605 of 5 stars$93.67+36.0%$92.73-1.0%+81.6%$5.21B$36.13M-17.0337Analyst ForecastHigh Trading VolumeKRYSKrystal Biotech4.4889 of 5 stars$176.75+5.3%$209.00+18.2%+9.8%$4.86B$290.52M35.92210Analyst ForecastPTCTPTC Therapeutics3.3953 of 5 stars$60.65+2.8%$69.00+13.8%+65.3%$4.69B$806.78M8.701,410Analyst ForecastInsider TradeMENSJyong BiotechN/A$50.00-16.3%N/AN/A$4.54BN/A0.0031Analyst ForecastARWRArrowhead Pharmaceuticals4.146 of 5 stars$33.78+3.0%$43.14+27.7%+102.1%$4.53B$3.55M-26.39400Analyst ForecastACLXArcellx2.321 of 5 stars$79.11-0.8%$114.31+44.5%+6.6%$4.42B$56.98M-23.1380News CoverageAnalyst ForecastPCVXVaxcyte2.3557 of 5 stars$34.65+2.0%$106.25+206.6%-62.5%$4.41BN/A-8.43160Positive NewsCRNXCrinetics Pharmaceuticals3.8682 of 5 stars$43.51-5.2%$73.20+68.2%-9.7%$4.32B$1.04M-10.59210Analyst ForecastPTGXProtagonist Therapeutics1.8995 of 5 stars$65.14-3.4%$68.36+4.9%+51.7%$4.19B$434.43M93.06120Analyst ForecastKYMRKymera Therapeutics1.6623 of 5 stars$58.50+4.0%$59.95+2.5%+31.6%$4.02B$47.07M-16.86170Analyst Forecast Related Companies and Tools Related Companies MRUS Alternatives KRYS Alternatives PTCT Alternatives MENS Alternatives ARWR Alternatives ACLX Alternatives PCVX Alternatives CRNX Alternatives PTGX Alternatives KYMR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STOK) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
